Andere Sprachen Acumen Pharmaceuticals, Inc.

Aktien

A3CTP6

US00509G2093

ABOS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 22.04.2024			% 5 Tage	% 1. Jan.
3,13 ^USD	-0,63 %		-11,33 %	-18,49 %

04.04.	Acumen Pharmaceuticals unterzeichnet Vertrag mit Lonza zur Herstellung eines Medikaments zur Behandlung von Alzheimer	MT
04.04.	Lonza schließt Herstellungsvertrag für Acumen's Alzheimer-Kandidat ab	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug at American Academy of Neurology 2024 Annual Meeting	17.04.
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting	16.04.
Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug	04.04.
Borsa svizzera chiude in rialzo, SMI +0,64%	04.04.
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate	04.04.
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease	04.04.
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease	04.04.
Acumen Pharmaceuticals Files $200 Million Mixed Shelf	27.03.
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights	26.03.
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting	21.03.
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting	21.03.
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024	19.03.
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024	19.03.
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days	12.03.
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days	12.03.
Acumen Pharmaceuticals : ADPD 2024 CSF Biomarker Presentation	08.03.
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting	08.03.
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting	08.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Acumen Pharmaceuticals, Inc.

Aktien

A3CTP6

US00509G2093

ABOS

Andere Sprachen

Filter